These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 15089732)

  • 21. The details are in the field.
    Schwab AP
    Am J Bioeth; 2010 Jan; 10(1):19-21. PubMed ID: 20077330
    [No Abstract]   [Full Text] [Related]  

  • 22. Drug detailers, professionalism, and prudence.
    Brody H
    Am J Bioeth; 2010 Jan; 10(1):9-10. PubMed ID: 20077325
    [No Abstract]   [Full Text] [Related]  

  • 23. The devil in the detail(ing).
    Morreim H
    Am J Bioeth; 2010 Jan; 10(1):15-7. PubMed ID: 20077328
    [No Abstract]   [Full Text] [Related]  

  • 24. Avoiding over-deterrence in managing physicians' relationships with industry.
    Stell LK
    Am J Bioeth; 2010 Jan; 10(1):27-9. PubMed ID: 20077334
    [No Abstract]   [Full Text] [Related]  

  • 25. Proposed guidelines for housestaff interaction with pharmaceutical companies.
    Forrest DM; Ruedy J
    Ann R Coll Physicians Surg Can; 1993 Oct; 26(5):291-3. PubMed ID: 15362243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Huddle gets it right, most docs don't.
    Rubin PH
    Am J Bioeth; 2010 Jan; 10(1):17-9. PubMed ID: 20077329
    [No Abstract]   [Full Text] [Related]  

  • 27. Why academic medical centers should ban drug company gifts to individuals.
    Strong C
    Am J Bioeth; 2010 Jan; 10(1):13-5. PubMed ID: 20077327
    [No Abstract]   [Full Text] [Related]  

  • 28. Doctors and drug companies.
    Lambert LA
    N Engl J Med; 2005 Feb; 352(7):733-4; author reply 733-4. PubMed ID: 15716575
    [No Abstract]   [Full Text] [Related]  

  • 29. The pitfalls of deducing ethics from behavioral economics: why the Association of American Medical Colleges is wrong about pharmaceutical detailing.
    Huddle TS
    Am J Bioeth; 2010 Jan; 10(1):1-8. PubMed ID: 20077321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pitfalls of misreading: what does "industry funding of medical education" actually say?
    Spielman B
    Am J Bioeth; 2010 Jan; 10(1):24-5. PubMed ID: 20077332
    [No Abstract]   [Full Text] [Related]  

  • 31. Industry relations with emergency medicine graduate medical education programs.
    Kowalenko T; Char D; Marco C; Asher S; Raja A; Farrell S; Sokolove PE;
    Acad Emerg Med; 2009 Oct; 16(10):1025-30. PubMed ID: 19799581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Icebreakers-unexpected outcomes.
    Jamshed SQ; Mohamed Ibrahim MI; Hassali MA
    J Coll Physicians Surg Pak; 2010 Feb; 20(2):142. PubMed ID: 20378048
    [No Abstract]   [Full Text] [Related]  

  • 33. Why self-regulation does not work: resolving prescription corruption caused by excessive gift-giving by pharmaceutical manufacturers.
    Mehta RS
    Food Drug Law J; 2008; 63(4):799-821. PubMed ID: 19593922
    [No Abstract]   [Full Text] [Related]  

  • 34. The AAMC exhibits the behavior it condemns.
    Stossel TP
    Am J Bioeth; 2010 Jan; 10(1):26-7. PubMed ID: 20077333
    [No Abstract]   [Full Text] [Related]  

  • 35. [Increase in incidence of drug treatments, ethical principles and conflict of interest in cooperation with the pharmaceutical industry].
    Hebebrand J; Blanz B; Herpertz-Dahlmann B; Lehmkuhl G
    Z Kinder Jugendpsychiatr Psychother; 2012 May; 40(3):133-8. PubMed ID: 22774235
    [No Abstract]   [Full Text] [Related]  

  • 36. [Physicians and drug industry: attitudes and practice].
    Aasland OG; Førde R
    Tidsskr Nor Laegeforen; 2004 Oct; 124(20):2603-6. PubMed ID: 15534631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do ethical Guidelines make a difference to decision-making?
    Osborn M; Day R; Komesaroff P; Mant A
    Intern Med J; 2009 Dec; 39(12):800-5. PubMed ID: 19323704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug sampling in dermatology.
    Reid EE; Alikhan A; Brodell RT
    Clin Dermatol; 2012; 30(2):192-201. PubMed ID: 22330663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Strategies for drug promotion].
    Polonuer JL
    Medicina (B Aires); 2005; 65(4):373-6. PubMed ID: 16193722
    [No Abstract]   [Full Text] [Related]  

  • 40. If 'atypical' neuroleptics did not exist, it wouldn't be necessary to invent them: perverse incentives in drug development, research, marketing and clinical practice.
    Charlton BG
    Med Hypotheses; 2005; 65(6):1005-9. PubMed ID: 16182461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.